Abstracts tagged "Cardiovascular disease"

Abstract Number: 475 • 2013 ACR/ARHP Annual Meeting
Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards
Birgul Ay¹, Dilek Keskin², Goksal Keskin³ and Ayhan Dinc⁴, ¹Internal Medicine, DYB Research and Training Hospital, Ankara, Turkey, ²Immunology, DYB Research and Training Hospital, Ankara, Turkey, ³Internal Medicine and Clinical Immunology, DYB Research and Training Hospital, Ankara, Turkey, ⁴Rheumatology, Patio Clinic, Ankara, Turkey
Background/Purpose: The proximal aorta accounts for most of the global arterial stiffening and subsequent complications. Aortic stiffness can be demonstrated by changes in aortic dimensions…
Abstract Number: 359 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Treatment Increases Left Ventricular Ejection Fraction and Decreases Left Ventricular Mass Index In Rheumatoid Arthritis Patients Without Cardiac Symptoms : Assessment By Cardiac Magnetic Resonance Imaging At 3.0 Tesla
Hitomi Kobayashi^1,2, Isamu Yokoe³, Hiroshi Sato², Yasuyuki Kobayashi⁴, Kihei Yoneyama⁵, Masaharu Hirano⁶ and Masami Takei⁷, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ³Nihon University School of Medicine, Tokyo, Japan, ⁴Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁵Cardiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁶Cardiology, Tokyo Medical Colleage, Tokyo, Japan, ⁷Division of Hematology and Rheumatology, NIhon University School of Medicine, Tokyo, Japan
Background/Purpose: Left ventricular (LV) dysfunction in rheumatoid arthritis (RA) may result, at least in part, from inflammation that may be regional and global. Therefore, therapies…
Abstract Number: 2221 • 2012 ACR/ARHP Annual Meeting
Major Adverse Cardiovascular Events Are More Common in Rheumatoid Arthritis Than in Psoriatic Arthritis and Are Associated with Different Risk Factors
Allen P. Anandarajah¹, Katherine C. Saunders², George W. Reed³, Alina U. Onofrei³, Jeffrey D. Greenberg⁴ and Christopher T. Ritchlin⁵, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Corrona, LLC., Southborough, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴NYU Hospital for Joint Diseases, New York, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Rheumatoid Arthritis (RA) is associated with increased cardiovascular mortality and morbidity rates. Similarly several studies have reported an increased risk for cardiovascular events in…
Abstract Number: 1265 • 2012 ACR/ARHP Annual Meeting
Lipoprotein Subclass Particles and Small Vessel Elasticity As a Potential Marker for Early Atherosclerosis in Rheumatoid Arthritis: a Prospective, Controlled Study
Marty T. Mertens¹ and Elie Gertner², ¹Rheumatology, University of Minnesota, Minneapolis, MN, ²Section of Rheumatology, Regions Hospital and University of Minnesota Medical School, St. Paul, MN
Background/Purpose: Rheumatoid arthritis (RA) has increased rates of cardiovascular (CV) events. However, standard CV risk factors, such as routine lipid profiles, are not different in…
Abstract Number: 640 • 2012 ACR/ARHP Annual Meeting
Association of Body Weight with Cardiovascular Events in Systemic Lupus Erythematosus
George Stojan¹, Homa Timlin², Hong Fang³, Laurence S. Magder⁴ and Michelle Petri³, ¹Division of Rheumatology, Harvard Medical School- Beth Israel Deaconess Medical Center, Boston, MA, ²West Drayton, United Kingdom, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Excessive body mass among healthy subjects carries an increased risk of subsequent cardiovascular (CV) events. In healthy subjects, the relationship between body mass index…
Abstract Number: 2180 • 2012 ACR/ARHP Annual Meeting
Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Primary Sjögren’s Syndrome
F. Atzeni¹, L. Boccassini¹, M.C. Signorello², MA Carrideo², L. Gianturco², V. De Gennaro Colonna³, L. Drago⁴, M. Turiel² and P. Sarzi-Puttini¹, ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²IRCCS Galeazzi Orthopedic Institute, University of Milan, Department of Health Technologies, Cardiology Unit,, Milan, Italy, ³Pharmacology Department, University of Milan, Milan, Italy, ⁴Laboratory Unit, IRCCS Galeazzi Orthopedic Institute, Department of Health Technologies, University of Milan, Milan, Italy
Background/Purpose: Clinical and biochemical data suggest that autoimmune diseases are associated with endothelial dysfunction and increased atherosclerosis. We have previously shown that asymmetric dimethylarginine (ADMA)…
Abstract Number: 1267 • 2012 ACR/ARHP Annual Meeting
Inflammatory Burden Predicts Progression of Carotid Plaque in Rheumatoid Arthritis: A 24-Month Longitudinal Analysis
Churl Hyun Im¹, Na Ri Kim¹, Jong Wan Kang¹, Young Ji Kim¹, Kyung Hye Kim¹, Eon Jeong Nam¹ and Young Mo Kang², ¹Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ²Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Carotid atherosclerosis, which is associated with the increased risk of cardiovascular (CV) disease, is increased in rheumatoid arthritis (RA) patients. In our previous study,…
Abstract Number: 623 • 2012 ACR/ARHP Annual Meeting
Endothelial Microparticles As a Biomarker for Endothelial Dysfunction in Active Systemic Lupus Erythematosus
Ben Parker¹, Awal Zaki², M. Yvonne Alexander³ and Ian N. Bruce⁴, ¹Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, ²Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, ³Healthcare Science Research Institute, Faculty of Science and Engineering, Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with an increased risk of clinical and subclinical cardiovascular disease (CVD) including endothelial dysfunction, in part due to…
Abstract Number: 2157 • 2012 ACR/ARHP Annual Meeting
Resveratrol Counters Pro-Atherogenic Effects of Systemic Lupus Erythematosus and Rheumatoid Arthritis Plasma On Cholesterol Efflux in Human Macrophages
Allison B. Reiss¹, Iryna Voloshyna¹, Ofek Hai¹, Michael J. Littlefield¹, Elise Belilos², Kristina B. Belostocki², Lois A. Bonetti³, Gary C. Rosenblum² and Steven E. Carsons⁴, ¹Medicine, Winthrop University Hospital, Mineola, NY, ²Rheumatology, Winthrop University Hospital, Mineola, NY, ³Rheum & Immun, Winthrop University Hospital, Mineola, NY, ⁴Div of Rheumatology, Winthrop University Hospital, Mineola, NY
Background/Purpose: Our group has demonstrated that resveratrol, a plant polyphenol, possesses atheroprotective properties, enhancing expression of reverse cholesterol transport (RCT) proteins. We have reported that Systemic…
Abstract Number: 1268 • 2012 ACR/ARHP Annual Meeting
Lipid Alterations and Measurement of Arterial Stiffness in Rheumatoid Arthritis
Marina Scolnik¹, Carla Saucedo², David A. Navarta³, Leandro Ferreyra Garrott², Erika Catay⁴, Maria L. Acosta Felquer⁵, Eliana Lancioni⁶, Cristian Quiroz³, Federica Varela Guidetti⁵, Zaida Bedran², Mirtha Sabelli⁴, Javier Rosa⁴, Maria Victoria Garcia⁴, Patricia M. Imamura⁵, Patricia Sorroche⁷, Jose Alfie⁸, Margarita Morales⁹, Gabriel Waisman⁹, Luis J. Catoggio¹ and Enrique Soriano¹, ¹Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Internal Medicine, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Internal Medicine, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷Central Laboratory , Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Internal Medicine, Hypertension Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁹Hypertension Section, Internal Medicine Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Increased arterial stiffness, an independent risk factor for premature coronary artery disease, has been reported in…
Abstract Number: 596 • 2012 ACR/ARHP Annual Meeting
Evolution of Atherosclerosis in Psoriatic Arthritis: Is the Former an Independent Inflammatory Process?
Roberta Ramonda¹, Massimo Puato², Valentina Modesti³, Mariagrazia Lorenzin⁴, Paola Frallonardo⁴, Augusta Ortolan⁴, Carla Campana³, Alessandro Lo Nigro³ and Leonardo Punzi⁵, ¹Rheumatology Unit, University of Padova, Padova, Italy, ²Department of Internal Medicine, University of Padova, Padova, Italy, ³Unit of Rheumatology, University of Padova, Padova, Italy, ⁴Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ⁵Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: A non-invasive study focusing on the structural and functional properties of the carotid arteries was carried out in psoriatic arthritis (PsA) patients. Increased cardiovascular…
Abstract Number: 1720 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Risk Management in Rheumatoid Arthritis Is Nurse Led Intervention Effective?
Fiona Niddrie¹ and Gabor AC Major², ¹Rheumatology, Bone and Joint Institute; Royal Newcastle Centre, Newcastle, Australia, ²Rheumatology, Bone&Joint Institute; Royal Newcastle Centre, Newcastle, Australia
Background/Purpose: There is a recognised increase in the incidence of heart disease in patients with rheumatoid arthritis (RA) Surveys of usual practice however frequently show…
Abstract Number: 1243 • 2012 ACR/ARHP Annual Meeting
Effect of Tocilizumab Treatment On Regional Left Ventricular Function, As Assessed by Cardiac Magnetic Resonance Imaging, in Rheumatoid Arthritis Patients without Cardiac Symptoms
Hitomi Kobayashi¹, Isamu Yokoe², Hiroshi Sato¹ and Yasuyuki Kobayashi³, ¹Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ²Nihon University School of Medicine, Tokyo, Japan, ³Radiology, St.Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of congestive heart failure, possibly via shared mechanisms of inflammation. This study was undertaken to…
Abstract Number: 480 • 2012 ACR/ARHP Annual Meeting
Etanercept Induces A Significant Decrease of Oxidative Stress and Osteoprotegerin Compared with Sdmard in Patients with Rheumatoid Arthritis
Claire I. Daien¹, Anne-Marie Dupuy Gorce², Edith Pinot², Thibault Mura³, Jean-Paul Cristol², Bernard Combe⁴ and Jacques Morel⁵, ¹Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ²Biochemistry, Hopital Lapeyronie, Montpellier, France, ³CIC, Hopital Gui De Chauliac, Montpellier, France, ⁴Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: TNF-inhibitors are known to decrease cardiovascular events in rheumatoid arthritis (RA) as compared with synthetic disease modifying anti-rheumatic drugs (sDMARD). However, mechanisms involved remain…
Abstract Number: 1702 • 2012 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Blocking Agents Inhibit the Progression of Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis
Alper M. van Sijl¹, Izhar C. van Eijk², Mike J.L. Peters³, Erik H. Serne³, Yvo M. Smulders⁴ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ⁴Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) is associated with an increased cardiovascular (CV) risk that might be due to the chronic underlying inflammatory process. It is still…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].